Slingshot members are tracking this corporate initiative:
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Do you think this event is important to the companies below? How will it affect their stock price?
Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019. In addition, AstraZeneca is eligible to receive up to $250 million in milestone payments, up to $600 million in sales-related payments, as well as tiered royalties on sales of Zavicefta and ATM-AVI in certain markets.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Aug 24, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q2, 2017
Don’t see a project related to the strategic initiative you care about?
Related Keywords Small Molecule Anti-infective Business